Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

BACKGROUND: Nivolumab has shown improved survival in the treatment of advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. We assessed the safety and activity of combination nivolumab plus ipilimumab as first-line therapy for NSCLC. METHODS: The open-label, phase 1, mult...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Oncol
Autors principals: Hellmann, Matthew D, Rizvi, Naiyer A, Goldman, Jonathan W, Gettinger, Scott N, Borghaei, Hossein, Brahmer, Julie R, Ready, Neal E, Gerber, David E, Chow, Laura Q, Juergens, Rosalyn A, Shepherd, Frances A, Laurie, Scott A, Geese, William J, Agrawal, Shruti, Young, Tina C, Li, Xuemei, Antonia, Scott J
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5476941/
https://ncbi.nlm.nih.gov/pubmed/27932067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30624-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars